​
​

Vincerx Pharma Stock (NASDAQ:VINC)

ForecastRevenueOwnershipFinancialsChart
Vincerx Pharma by TradingView

Previous Close

$0.27

52W Range

$0.26 - $9.37

50D Avg

$0.50

200D Avg

$1.51

Market Cap

$9.25M

Avg Vol (3M)

$541.75K

Beta

1.27

Div Yield

-

VINC Company Profile

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

42

IPO Date

May 27, 2020

Website

VINC Performance

VINC Financial Summary

Dec 23Dec 22Dec 21
Revenue---
Operating Income$-42.61M$-73.57M$-62.66M
Net Income$-40.16M$-57.16M$-15.61M
EBITDA$-41.69M$-74.94M$-86.01M
Basic EPS$-1.89$-2.72$-0.91
Diluted EPS$-1.89$-2.72$-0.91

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

TickerCompany
SNTISenti Biosciences, Inc.
GRCLGracell Biotechnologies Inc.
SIOXSio Gene Therapies Inc.
FRTXFresh Tracks Therapeutics, Inc.
APLTApplied Therapeutics, Inc.
MNPRMonopar Therapeutics Inc.
XOMAXOMA Corporation
BCABBioAtla, Inc.
SPROSpero Therapeutics, Inc.
SRZNSurrozen, Inc.
BOLTBolt Biotherapeutics, Inc.
VCNXVaccinex, Inc.
LVTXLAVA Therapeutics N.V.
RZLTRezolute, Inc.
PCSAProcessa Pharmaceuticals, Inc.
TARAProtara Therapeutics, Inc.
NLTXNeurogene Inc.
CHRSCoherus BioSciences, Inc.
LYRALyra Therapeutics, Inc.
STTKShattuck Labs, Inc.